Krishna Institute Of Medical Sciences Limited · NSE:KIMS
Krishna Institute Of Medical Sciences — Q4 FY2022 Earnings Presentation
38 slides from Krishna Institute Of Medical Sciences's earnings presentation, May 24, 2022
Slide 1: Letter to stock exchanges on updated investor presentation
\KKrMs D HosPtrALS- 24'h M^y,2022 The Genetal Managet, The Manager, Depanrnent of Cotpotate sewices Lisring Departrnent Bombay Stock Exchange Ltd (BSE) National Stock Exchange of India Limited, Phiroze Jheejheebhoy Towers, Exchange Plzz4 5th Floor, Dalal Sreet, PIot No.C/1, 'G' Block Mumbai - 400 00
Slide 2: Making Quality Healthcare Accessible & Affordable
MAKING QUALITY HEALTHCARE ACCESSIBLE & AFFORDABLE Private & Confidential
Slide 3: Dominant and the Largest Corporate Healthcare Group in AP & Telangana
DOMINANT AND THE LARGEST CORPORATE HEALTHCARE GROUP IN ANDHRA PRADESH & TELANGANA KIMS KIMS KIMS KIMS NELLORE RAJAHMUNDRY ONGOLE SRIKAKULAM KIMS KIMS-ICON KIMS-SAVEERA KIMS KONDAPUR VIZAG ANANTAPUR KURNOOL KIMS KIMS-SUNSHINE KIMS-SUNSHINE KIMS-SUNSHINE SECUNDERABAD SECUNDERABAD GACHIBOWLI KARIMNAGAR
Slide 4: Driven by a Vision
DRIVEN BY A VISION Affordable Quality Care Best-in-Class Facilities Patient Centric Systems & Processes S NT VISION: TIE PA To be the most preferred Clinical Outcome Driven Excellence R S healthcare services C TO Latest Medical Technology D O brand by providing Strong Academics & Research Oriented a
Slide 5: Multi Specialty Care
MULTI SPECIALTY CARE Brain Eyes Bones and Spine Radiology • Neurology • Ophthalmology • Orthopedics • Imaging • Neurosurgery Gastro Intestinal Tract • Arthroscopic Surgery • Interventional Radiology • Psychiatry • Medical Gastroenterology • Spine Surgery Lab Services • Neuro Rehabilitation • Surgica
Slide 6: KIMS Geographic Presence
KIMS GEOGRAPHIC PRESENCE Telangana Map Andhra Pradesh Map Hyderabad Map Kondapur Srikakulam Secunderabad Vizag Rajahmundry Paradise Circle Kurnool Karimnagar Gachibowli Ongole Hyderabad Nellore Anantapur Map not to scale 5 Private & Confidential
Slide 7: Dr. B. Bhaskar Rao - Visionary Behind KIMS
DR. B. BHASKAR RAO - VISIONARY BEHIND KIMS Managing Director A legend in CT Surgery, Dr. Bollineni Bhaskar Rao {MBBS, MS, DNB (CT Surgery)} is one of the very few Cardio- Thoracic Surgeons in the country, who performed over 30000 surgeries in his career spanning over more than 25 years. Well known i
Slide 8: Dr. Abhinay Bollineni
DR. ABHINAY BOLLINENI Chief Executive Officer Dr. Abhinay Bollineni joined KIMS Hospitals in 2013 and spent the next couple of years in Hospital Operations before taking charge of Strategy & Marketing for the Group in 2015. In a short span of 5 years, KIMS expanded and opened five additional units (
Slide 9: Board of Directors
BOARD OF DIRECTORS Mr. Saumen Chakraborty Dr. Bhaskara Rao Bollineni Dr. Abhinay Bollineni Mrs. Anitha Dandamudi Shantanu Rastogi Independent Director, Managing Director Chief Executive Officer Whole-time Director Non-Executive Director Chairman (Audit Committee) Mr. Pankaj Vaish Mr. Rajeswara Rao G
Slide 10: Shareholding Pattern - 31 March 2022
SHAREHOLDING PATTERN - 31 MARCH, 2022 ST Clearing Members, ICICI Ventures, 2.4% 0.2% As on 31st March 2022 Top Shareholders - DII / FII Retail,13.4% Share Holder Share Holding % Category Promoter & Promoter General Atlantica 17.24% FII Group, 38.8% ICICI Ventures 2.42% DII Mirae Asset MF 7.1% DII Ax
Slide 11: Modern Medical Technology
MODERN MEDICAL TECHNOLOGY 4-Arm HD da Vinci O-Arm Scanner Spy Glass Robotic Surgical Multi-dimensional surgical State of the art add on to System imaging platform optimized ERCP that allows doctors to Facilitates complex for use in spine, orthopaedic, observe patients’ biliary duct surgeries that ar
Slide 12: Many Firsts...
MANY FIRSTS... • First in Asia in to do Trans catheter • India’s first COVID Double Lung • Number 1 in Nephrology treatments in Tricuspid Valve replacement transplant done in 2020 Andhra Pradesh* procedure done in 2018 • India’s first Breathing Lung transplant • Number 1 in Neurosurgery & Poly • Lar
Slide 13: Key Accomplishments
KEY ACCOMPLISHMENTS Pharmacie De Qualite (PDQ) ‘Best Patient Friendly Hospital’ ‘Best Hospital to Work For’ Certification Overall PDQ Evaluation Ranked No. 1 Hospital AHPI Health Care Excellence AHPI Global Conclave Performance Score - 98% by Times of India, Hyderabad Award (2017) Award (2019) Gradi
Slide 14: Awards and Accolades
AWARDS AND ACCOLADES 2016 2017 2019 Neurology Department at KIMS Secunderabad KIMS Sec. Best Super-Specialty KIMS Secunderabad Best Hospital of the Year Hospital in Telangana ranked 3rd in India Times Healthcare National Quality Neurology India General Achievers Awards Excellence Awards 2021 2020 Ra
Slide 15: Consistent Performer Over 2 Decades
CONSISTENT PERFORMER OVER 2 DECADES (Rupees in Millions) 16,711 Industry leading ROCE Total income has grown approx. 64 times 11,287 in last 17 years 4,280 5,360 1,311 330 857 2,511 263 32% 25% 22% 20% 46 17% EBITDA% Total Income EBITDA% Total Income EBITDA% Total Income EBITDA% Total Income EBITDA%
Slide 16: Financial & Operational Highlights
FINANCIAL & OPERATIONAL HIGHLIGHTS FINANCIAL Q4 FY 21-22 HIGHLIGHTS • Total Income saw an increase of 5% against Q4 of FY 21, standing at Rs. 3,805 million. • Consolidated EBITDA for Q4 FY 22 stood at Rs. 1,218 million, a growth of 16% against Q4 FY 21. EBITDA margins expansion was driven by special
Slide 17: Digital & ESG Initiatives
DIGITAL & ESG INITIATIVES DIGITAL During the quarter, steady progress was made on digital transformation with notable initiatives as below: INITIATIVES • Remote patient monitoring technology was deployed in the wards, integrated with a digital nursing application. • Digital applications were flexibl
Slide 18: Group Operating Performance - 1/3
GROUP OPERATING PERFORMANCE - 1/3 IP VOLUME OP VOLUME 140,676 1,137,560 136,731 1,013,759 900,043 111,382 116,592 830,211 88,577 661,000 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 OCCUPANCY* ARPOB 25,323 20,609 58.5% 57.6% 55.7% 51.4% 48.7% 18,807 18,334 18,307 FY18 FY19 FY20 FY21 FY22 FY18 F
Slide 19: Group Operating Performance - 2/3
GROUP OPERATING PERFORMANCE - 2/3 Adj. REVENUE Adj. EBITDA 16,711 5,360 13,401 3,810 11,287 2,511 9,239 1,740 6,672 1,394 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 Adj. PBT Adj. PAT 4,569 3,438 2,790 2,054 1,405 1,150 691 838 434 503 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 1. Above
Slide 20: Group Operating Performance - 3/3
GROUP OPERATING PERFORMANCE - 3/3 Particulars FY18 FY19 FY20 FY21 FY22 Bed Capacity 2,120 2,804 3,004 3,064 3,064 Occupancy 51.4% 48.7% 55.7% 57.6% 58.5% IP volume 88,577 111,382 140,676 116,592 136,731 OP volume 661,000 900,043 1,137,560 830,211 1,013,759 ARPOB 18,807 18,334 18,307 20,609 25,323 AR
Slide 21: Group Operating Performance 1/2
GROUP OPERATING PERFORMANCE 1/2 IP VOLUME OP VOLUME -0.4% 3.4% 36,205 36,229 261,867 280,385 279,978 270,897 31,790 32,732 32,588 256,590 28,865 31,709 23,203 181,201 182,499 130,553 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 Q3 FY
Slide 22: Group Operating Performance 2/2
GROUP OPERATING PERFORMANCE 2/2 REVENUE EBITDA 4.9% 15.9% 4,775 1,479 4,171 1,428 1,342 4,112 3,960 1,322 3,608 3,627 3,805 1,218 1,051 931 2,055 401 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 FY 21 FY 22 FY 21 FY 2
Slide 23: Comparison of AP Mature Hospitals & AP Acquired Hospitals
COMPARISON OF ANDHRA PRADESH MATURE HOSPITALS & ANDHRA PRADESH ACQUIRED HOSPITALS Matured Assets Acquired Assets Particulars Bed Capacity: FY19 FY20 FY21 FY22 FY19 FY20 FY21 FY22 New Clinical specialities of Oncology, Vascular Surgeries and Mother & Child are Bed Capacity 570 570 630 630 1034 1234 1
Slide 24: Speciality, Payor & Cluster Profile
SPECIALITY, PAYOR & CLUSTER PROFILE (FY22) SPECIALITY MIX PAYOR MIX CLUSTER REVENUE* AP Non Mature 20% Aarogyasri Telangana Cardiac Science 9.5% 67% 17% FY22 Corporate Cash AP 10.1% 60.2% Mature 13% Others 37% Neuro Science 11% FY22 FY22 CLUSTER EBITDA* Renal Science AP Non Mature Insurance 13% 9% 2
Slide 25: Sunshine Hospital - Our Latest Acquisitions
SUNSHINE HOSPITAL - OUR LATEST ACQUISITIONS Dr. A.V. Gurava Reddy Dr. A. Bhavani Managing Director Director • Started in 2009. Currently 600+ beds. SECUNDERABAD GACHIBOWLI KARIMNAGAR • Second largest Orthopedic practice in South East Asia • 1st Hospital in INDIA with ISOC Membership The upcoming new
Slide 26: Sunshine Hospitals - Consolidated Financial Snapshot (P&L)
SUNSHINE HOSPITALS -CONSOLIDATED FINANCIAL SNAPSHOT (P&L) Ind AS P&L Summary (In INR Mn) Nov-Mar ‘22 (5 Months) Revenue (Inc. Other Income) 1867.2 EBITDA 488.0 EBITDA % 26.1% Finance Cost 38.7 Depreciation 115.2 PBT 334.1 PAT 225.0 EBITDA 488.0 IND AS Adjustment -85.3 EBITDA - Pre Ind AS 402.7 Adjus
Slide 27: Key Achievements in Q4 FY22
KEY ACHIEVEMENTS IN Q4 FY22 World’s first auto guide Doctors give prosthetic Complex case of implantation for Deep testis to a 23-year- Tail Gut Cyst treated Brain Stimulation old who had lost successfully by using AI done by it due to genetic Doctors at KIMS Neurosurgeons at reasons in childhood Ho
Slide 28: Key Achievements in Q4 FY22
KEY ACHIEVEMENTS IN Q4 FY22 42 year old gives birth 10 months baby Complex case of to preterm babies successfully pituitary tumor treated successfully at KIMS undergoes complex successfully at KIMS Saveera, Anantapur kidney surgery at KIMS ICON, Vizag Saveera, Anantapur Critical procedure of In a ra
Slide 29: Key to Our Success
KEY TO OUR SUCCESS Doctor Affordable Partnerships Quality Care Modern Medical Infra 28 Private & Confidential
Slide 30: Disciplined Growth Strategy - Growing in Adjacent Markets
KIMS HAS A DISCIPLINED GROWTH STRATEGY - STRATEGICALLY GROW IN ADJACENT MARKETS SOME OF WHICH ARE ‘NATURAL EXTENSIONS’ KIMS Plans to Grow into Markets that are Adjacent to the Current Core Markets of AP and Telangana Central & Western India (Indore, Aurangabad, Nagpur & Raipur): KIMS flagship hospit
Slide 31: Update on Expansion Plans
Update on Expansion Plans 30 Private & Confidential
Slide 32: Maharashtra Strategy
MAHARASHTRA STRATEGY • Maharashtra is an important market for future expansion for us. Nagpur Amravati • KIMS Secunderabad gets a steady influx of Akola patients from Vidarbha (Nagpur, Akola, Amravati) and Marathwada (Nanded, Latur, Aurangabad, Aurangabad Nashik etc) regions and therefore there is d
Slide 33: Proposed Nashik Hospital
PROPOSED NASHIK HOSPITAL Physical Infrastructure Medical Infrastructure: Proposed Manpower • 325 beds hospital • 2 Cath Labs • 70 full time Clinicians • 69 ICU beds • 1 MRIs • 20 support department • 1 CT • 8 OTs clinicians • Endoscopy Suite / • Patient Rooms Break Up ERCP Suite • 1400 staff - 31 Si
Slide 34: Proposed Nashik Hospital Departments
PROPOSED NASHIK HOSPITAL DEPARTMENTS Brain Gastro Intestinal Tract Skin Transplant Services • Neurology • Medical Gastroenterology • Dermatology • Heart Transplant • Neurosurgery • Surgical Gastroenterology • Cosmetology • Lung Transplant • Psychiatry • Hepatobiliary Pancreatic Surgery • Plastic and
Slide 35: Expansion Plans
EXPANSION PLANS Current Incremental New Approx. Approx. Timeline Units Beds Beds Departments Capex (Starting April 2021) Kondapur 200 500 All Specialities 300 Cr 36-42 months Vizag 434 50 Cancer Centre 15-20 Cr 24 months Cancer Centre / Anantapur 250 150 50-60 Cr 36-48 months Mother & Child Ongole 3
Slide 36: Profit and Loss Statement
PROFIT AND LOSS STATEMENT (RS. MILLIONS) Particulars FY 22 FY 21 (%) Q4 FY 22 Q3 FY 22 Q2 FY 22 Q1 FY 22 Q4 FY 21 QoQ(%) YoY(%) Total Income 16,710.9 13,401.0 24.7% 3,805.3 3,959.6 4,171.5 4,774.5 3,627.3 -3.9% 4.9% Material cost 3,551.6 2,889.3 751.2 821.8 855.2 1,123.4 772.9 Employee benefit expen
Slide 37: Corporate Structure
CORPORATE STRUCTURE Krishna Institute of Medical Sciences Ltd. KIMS Secunderabad KIMS Nellore KIMS Rajahmundry KIMS Ongole (100%) (100%) (100%) (100%) AHPL KHEPL KIMS ICON KIMS Saveera KIMS Rainbow Sarvejana Srikakulam Kondapur Vizag Anantapur Kurnool (Sunshine) (57.8%) (86.3%) (51.0%) (80.0%) (55.0
Slide 38: Thank You
Thank You 37 Private & Confidential
Krishna Institute of Medical Sciences — Q4 FY2022 Earnings Presentation on 6ix